CCM/Market Reports-/Future of Red Biotechnology in China

¡¡

(home)
CCM
consultancy
Market reports
Trade Analysis
newsletters & Information
conferences & events
coming report
ValoTracer
about us
careers 
contact
Always Primary Findings
Online Payment
samples
 

click here for sample pages

 

CCM>Market Reports>

 

No. 0041R001 Future of Red Biotechnology in China  - Edition(1)

 

 

About This Report:

 

Report edition:  2010 edition(1)
Language version: English
Document type: PPT document with additional Excel Document
For ready report --    
  Finished in: Apr 2010 ,edition(1)
  Total pages: 178
  Delivery: Delivery within 1-1 work days by email
  Price/copy: - USD10000.00 for single user
    -USD25000.00 for corporate license/site license
For update report --  
  Delivery time: Delivery within 20-30 work days by email
  Price/copy: - USD12000.00 for single user PDF
    - USD30000.00 for corporate license/site license

 

* The corporate license/site license is only for the sole and confidential use within the subscriber company and its affiliates in which the subscriber company owns, directly or indirectly, a fifty percent or greater, financial interest.

 

Report Edition List:

 

Version Finished in Availability Language   Pages   Delivery Price/Copy (For single user)
update report - update on request English - within 20-30 work days by email USD12000.00

 

 

Description:

 

Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and it has become the most important part in biotechnology industry. About 60% of achievements in biotechnology in the world are applied in production of bio-pharmaceuticals. At present, RB products mainly include gene recombinant drugs, blood products, vaccines, diagnostic reagents, etc. What is the current production situation of different RB products in China?

Driven by its substantial environmental or economic benefits, China’s RB industry has witnessed fast development and has played an increasingly important role in Chinese economic growth. However, the overall development of China’s RB industry remains in growth stage, and still has an enormous gap compared with developed countries. What is the future trend of Chinese RB industry development? What are the relevant supporting policies on Chinese RB industry? What have been the popular cutting-edge technologies in China in recent years? Where are the investment opportunities and what is the investment mode in China?

What is covered in this report?

- Overview of China’s red biotechnology;
- Detailed analysis of each sub-categories of red biotechnologies in China: gene recombinant drugs, blood products, vaccines, diagnostic reagent, etc., in terms of market data, major players, technical suppliers, technologies or R&D situations;
- Future prospects of each category of red biotechnologies, with key influencing factors and commercial opportunities
- Profiles of major players and research institutes
- Related policies and regulations

What benefits will you get?

- Gain a clear understanding about the industry landscape and latest developments in R&D, production, technology advancement and future trends in China’s red biotechnology;
- Keep informed of the precise development situation of key RB products with basic data and latest info;
- Gain reasonable and constructive suggestions on market opportunities in China’s RB fields;
- Figure out, current trend and future growth prospect of red biotechnology in China;
- Know more about how innovative players and research groups are carrying out innovation, collaboration and achieving commercial success in China.

 

Main Content:

 

No. Content
Page
Executive summary
1
Methodology & sources
3
I Overview of red biotechnology in China
5
Introduction to red biotechnology
5
Role of red biotechnology in medicine industry
5
Overview of red biotechnology development
6
II Development environment of red biotechnology in China
9
II-1 Macro economic environment
9
II-2 Policy environment
11
II-3 Medicine industry development
13
II-4 Venture capital
14
III Market segments of red biotechnology industry in China
16
III-1 Gene recombinant drugs
16
III-1.1 Erythropoietin（EPO）
16
III-1.2 Insulin
19
III-1.3 G-CSF
24
III-1.4 Rh-GH
25
III-1.5 Interferon
29
III-1.6 Anti-tumor monoclonal antibody
30
III-2 Blood products
36
III-3 Human vaccines
45
III-4 Diagnostic reagent
61
III-4.1 Diagnostic reagent history in China
62
III-4.2 Current production situation in China
63
III-4.3 Producers information of Chinese diagnostic reagent
64
III-4.3.1 Biochemical diagnostic reagent
65
III-4.3.2 Immunodiagnostic reagent
66
III-4.3.3 Molecular diagnostic reagent
67
III-4.3.3.1 PCR reagent
67
III-4.3.3.2 Biochips
68
III-4.4 Forecast
69
III-5 Other red biotechnology based drugs
70
III-5.1 Antibiotic
70
III-5.1.1 Current antibiotic production in China
70
III-5.1.2 Penicillin production technology
71
III-5.1.3 Waste treatment technology
73
III-6 Forecast on supply & demand to the next 5~10 years
74
III-6.1 Forecast on gene recombinant market during 2010~2020
74
III-6.1.1 Supply of gene recombinant drugs during 2000~2020
75
III-6.1.2 Demand for gene recombinant drugs during 2009~2020
77
III-6.1.3 Difference between demand and supply during 2009~2020
77
III-6.2 Forecast on blood product market during 2010~2020
78
III-6.2.1 Supply of blood products during 2005~2020
78
III-6.2.2 Demand for blood products during 2009~2020
79
III-6.2.3 Difference between demand and supply during 2009~2020
79
III-6.3 Forecast on human vaccine market during 2010~2020
79
III-6.3.1 Supply of human vaccines during 2005~2020
80
III-6.3.2 Demand for human vaccines during 2009~2020
81
III-6.3.3 Difference between demand and supply during 2009~2020
81
III-6.4 Forecast on diagnostic reagent market during 2010~2020
81
III-6.4.1 Supply of diagnostic reagents during 2005~2020
82
III-6.4.2 Demand for diagnostic reagents during 2009~2020
83
III-6.4.3 Difference between demand and supply during 2009~2020
83
IV Cutting edge technology development in China
84
IV-1 Stem cell treatment
84
IV-2 Monoclonal antibody
85
IV-3 Diagnostic reagent
86
IV-4 Vaccine
87
V Geographical distribution of China’s red biotechnology industry
89
V-1 Regional distribution
89
V-2 Introduction to RB industrial clusters
89
V-3 Overview of major RB industrial bases
90
V-3.1 Changsha Natioanl Biomedical Industrial Base
90
V-3.2 Zhangjiang National Biomedical Industrial Base
93
V-3.3 Zhongguancun National Biomedical Industrial Base
95
V-3.4 Shenzhen National Biological Industry Base
99
V-3.5 Changchun National Biological Industry Base
99
V-3.6 Guangzhou National Biological Industry Base
99
V-3.7 Shijiazhuang National Biological Industry Base
100
V-4 Forecast on national biological industry base in the next 5~10 years
100
VI Analysis of main Chinese companies in red biotechnology
102
VI-1 Choice of main Chinese companies in red biotechnology industry
102
VI-2 Analysis on main Chinese companies in red biotechnology industry
104
VI-2.1 Company engaged in biotech drugs
104
- Shanghai FOSUN Pharmaceutical (GROUP) Co., Ltd.
VI-2.2 Companies engaged in blood products
107
- Shanghai RAAS Blood Products Co., Ltd.
- Hualan Biological Engineering, Inc..
VI-2.3 Company engaged in vaccine
112
- Beijing Tiantan Biological Products Co., Ltd.
VI-2.4 Company engaged in bio-engineering drugs
114
- Beijing SL Pharmaceutical Co., Ltd.
VI-2.5 Company engaged in antibiotics
116
- Shandong Lukang Pharmaceutical Co., Ltd.
VI-2.6 Company engaged in diagnostic reagents
118
- Shanghai Kehua Bio-Engineering Co., Ltd.
VII Main foreign involvement in China’s red biotechnology
123
VII-1 Foreign companies in China
123
VII-1.1 GlaxoSmithKline (China) Co., Ltd.
123
VII-1.2 Pfizer (China) Co., Ltd.
127
VII-1.3 Novartis (China) Co., Ltd.
128
VII-1.4 Sanofi Pasteur (China) Co., Ltd.
131
VII-2 Comparison of foreign companies and Chinese companies
134
VII-3 Forecast on foreign involvement in China in next 5~10 years
135
VII-3.1 Forecast on Novartis expansion in China
136
VII-3.2 Forecast on GSK expansion in China
137
VII-3.3 Forecast on Sanofi-aventis expansion in China
137
VIII Analysis of investment in the next 5 years
139
VIII-1 Investment opportunities in biopharmaceutical industry
139
VIII-1.1 Solid foundation of bio-pharmaceutical investment
139
VIII-1.2 Investment hotspots in China
143
VIII-2 Risk analysis of the investment in China’s red biotechnology
146
VIII-2.1 Risk from international environment
146
VIII-2.2 Risk from domestic environment
146
VIII-2.3 Estimation of bio-pharmaceutical investment risk in the next 5 years
152
IX Profiles of key players in China
155
IX-1 Companies
155
IX-1.1 Gene recombinant drugs
155
IX-1.2 Blood products
160
IX-1.3 Vaccine
164
IX-1.4 Diagnostic reagent
168
IX-2 Research institutes
172

LIST OF TABLES
Table II-1.1 Annual benchmark lending rate of RMB
Table II-2 Relevant policies on bio-pharmaceutical industry in China, 2006-2009
Table II-3.1 Medicine industry output value in China, 2004-2008, billion USD
Table III-1.1.1 Market share of major EPO manufacturers, 2009
Table III-1.2.1 Three generations of insulin
Table III-1.2.2 Main rh-insulin manufacturers in China, 2009
Table III-1.3.1 Output of some G-CSF manufacturers, 2008
Table III-1.4.1 Market share of main rh-GH manufacturers in China, 2006-2008
Table III-1.5.1 Top four interferon manufacturers in China, 2009
Table III-1.5.2 Market share of main interferon manufacturers in China, 2006-2008
Table III-1.6.1 List of imported anti-tumor monoclonal antibody drugs
Table III-1.6.2 List of domestic anti-tumor monoclonal antibody drugs
Table III-2.1 Some major human albumin manufacturers in China, 2010
Table III-2.2 Human albumin output of major manufacturers in China, 2008-2009
Table III-2.3 Human immunoglobulin for intravenous injection output of major manufacturers, 2009
Table III-3.1 Vaccines belonging to National Immunization Program, 2010
Table III-3.2 Average import and export prices of human vaccines, 2006-2009
Table III-3.3 Production situation of H1N1 Influenza A Vaccine in China, 2010 (Unit: thousand doses)
Table III-3.4 Monthly lot release volume of top 4 H1N1 Influenza A vaccine in China, Sep-Dec. 2009 (Unit: thousand doses)
Table III-3.5 All Inactivated Split Influenza vaccine lot release in China, 2009
Table III-3.6 Situation of domestic HBV lot release, 2007-2009 (unit: thousand doses)
Table III-3.7 Major manufacturers’ HBV lot release situation, 2009 (unit: thousand doses)
Table III-3.8 Lot release volume of some major human vaccines, 2007-2009
Table III-4.1 Comparison of three main diagnostic reagents
Table III-4.3.1 Major diagnostic reagent producers in China, 2008
Table III-4.3.1.1 Top 3 producers of biochemical diagnostic reagents in China, 2008
Table III-4.3.2.1 Some producers of immunodiagnostic reagent in China, 2008
Table III-4.3.3.1.1 Major PCR reagent producers in China, 2008
Table III-4.3.3.2.1 Some biochips producers in China, 2009
Table III-6.1.1.1 Supply of four gene recombinant drugs in China, 2000-2020
Table III-6.1.1.2 Supply of gene recombinant drugs in China, 2009-2020
Table III-6.1.2.1 Demand for gene recombinant drugs in China, 2009-2020
Table III-6.1.3.1 Demand & supply gap of gene recombinant drugs in China, 2009-2020
Table III-6.2.1.1 Supply of blood products in China, 2005-2020
Table III-6.2.2.1 Demand for blood products in China, 2009-2020
Table III-6.2.3.1 Demand & supply gap of blood products in China, 2009-2020
Table III-6.3.1.1 Supply of human vaccines in China, 2005-2020
Table III-6.3.2.1 Demand for human vaccines in China, 2009-2020
Table III-6.3.3.1 Demand & supply gap of human vaccines in China, 2009-2020
Table III-6.4.1.1 Supply of diagnostic reagents in China, 2005-2020
Table III-6.4.2.1 Demand for diagnostic reagents in China, 2009-2020
Table III-6.4.3.1 Demand & supply gap of diagnostic agents in China, 2009-2020
Table IV-3.1 Info about HIV diagnostic kit of different generation
Table V-1.1 Top 10 RB industrial regions by output value in China, 2008
Table V-1.2 Top 10 RB industry regions by profit, 2008
Table V-2.1 Seven National Biomedical Industrial Bases
Table V-3.1.1 Eight investment sectors of this Base
Table V-3.1.2.1 Incentives provided by the Base
Table V-3.1.2.2 High-quality research centers in the Base
Table V-3.2.2.1 Professional organizations
Table V-3.2.2.2 Venture Service Centre
Table V-3.3.2.1 Platform of Bio-technology
Table V-3.3.2.2 Animal base
Table V-3.3.2.3 R&D support
Table V-3.3.2.4 Main equipments and instruments in second-stage test workshop
Table V-3.5.1 Research centers
Table VI-1.1 Major listed bio-pharmaceutical companies and their achievements
Table VI-2.1.1 Employee structure in Shanghai FOSUN
Table VI-2.1.2 Business performance of Shanghai FOSUN by field and product, H1 2009
Table VI-2.1.3 Business performance of Shanghai FOSUN in different regions, H1 2009
Table VI-2.1.4 Financial indicators of Shanghai FOSUN, 2007- 2009
Table VI-2.2.1 Main products of Shanghai RAAS
Table VI-2.2.2 Employee structure of Shanghai RAAS
Table VI-2.2.3 Business performance of Shanghai RAAS by field and product, H1 2009
Table VI-2.2.4 Business performance of Shanghai RAAS in different regions, H1 2009
Table VI-2.2.5 Financial indicators of Shanghai RAAS, 2007 - 2009
Table VI-2.2.6 Employee structure of Hualan Biological
Table VI-2.2.7 Business performance of Hualan Biological by field and product, H1 2009
Table VI-2.2.8 Business performance of Hualan Biological in different regions, H1 2009
Table VI-2.2.9 Financial indicators of Hualan Biological, 2007- 2009
Table VI-2.3.1 Employee structure of Tiantan Biological
Table VI-2.3.2 Business performance of Tiantan Biological by product, H1 2009
Table VI-2.3.3 Business performance of Tiantan Biological, H1 2009
Table VI-2.3.4 Financial indicators of Tiantan Biological, 2007- 2009
Table VI-2.4.1 Employee structure of Beijing SL
Table VI-2.4.2 Business performance of Beijing SL by field and product, H1 2009
Table VI-2.4.3 Business performance of Beijing SL in different regions, H1 2009
Table VI-2.4.4 Financial indicators of Beijing SL, 2007-2009
Table VI-2.5.1 Employee structure of Shandong Lukang
Table VI-2.5.2 Business performance of Shandong Lukang by product, H1 2009
Table VI-2.5.3 Business performance of Shandong Lukang in different regions, H1 2009
Table VI-2.5.4 Financial indicators of Shandong Lukang, 2007- 2009
Table VI-2.6.1 R&D Events reflecting research capability of Shanghai Kehua, 2005~2009
Table VI-2.6.2 Four major diagnostic reagents of Shanghai Kehua
Table VI-2.6.3 Employee structure of Shanghai Kehua
Table VI-2.6.4 Business performance of Shanghai Kehua by field and product, H1 2009
Table VI-2.6.5 Business performance of Shanghai Kehua in different regions, H1 2009
Table VI-2.6.6 Financial indicators of Shanghai Kehua, 2007-2009
Table VII-1.1.2.1 Prescription medicines introduced by GSK China into China
Table VII-1.1.2.2 Vaccines introduced by GSK China into China
Table VII-1.1.2.3 OTC medicines marketed by GSK China in China
Table VII-1.1.2.4 Healthcare products of GSK China in China
Table VII-1.4.2.1 Bacterial diseases and viral diseases
Table VII-2.1 Financial performance comparison of Chinese and overseas biopharmaceutical companies, 2008-2009
Table VII-3.1.1 Industry sales and growth of Novartis, 2010~2015
Table VII-3.2.1 Industry sales and growth of GSK, 2009
Table VII-3.3.1 Sanofi-aventis industry sales and growth in 2008 and 2009
Table VIII-1.1.1 Main bio-industry policies
Table VIII-2.2.1 regulatory policies and main impacts
Table VIII-2.2.2 Important regulatory policies about blood product industry
Table VIII-2.2.3 Average R&D expenses of different era in the world
Table VIII-2.2.4 Domestic higher education graduates of biochemical pharmaceutical major
Table VIII-2.2.5 Employees of bio-chemical and bio-pharmaceutical enterprises
Table VIII-2.3.1 Estimated values of investment risks and EVBIR

LIST OF FIGURES
Figure I.1 Output value of bio-pharmaceuticals in China, 2004-2009
Figure I.2 Proportion of bio-pharmaceuticals in China’s medicine industry, 2009
Figure I.3 RB industrial output value changes in the proportion of China’s GDP, 2004-2009
Figure II-1.1 China’s GDP growth, 2004-2009
Figure II-2.1 Per capita disposable income of urban residents in China, 2004-2009
Figure II-3.1 Medicine industry output value in China, 2004-Nov.2009
Figure II-4 Procedure of venture capital in bio-pharmaceutical industry
Figure III-1.1.1 EPO market value in China, 1999-2009
Figure III-1.1.2 Forecast on EPO market value, 2010-2014
Figure III-1.2.1 Global l insulin market value structure, 2009
Figure III-1.2.2 Insulin market value structure in China, 2009
Figure III-1.2.3 Output of rh-insulin in China, 2007-2009
Figure III-1.2.4 Number of global diabetes patients, 1985-2007
Figure III-1.2.5 Number of diabetes patients in China, 1978-2007
Figure III-1.2.6 Market value of insulin in China, 2005-2009
Figure III-1.2.7 Insulin import and export under HS code 29371200 in China, 2006-2009
Figure III-1.2.8 Insulin import and export under HS code 30043100 in China, 2006-2009
Figure III-1.2.9 Forecast on insulin market value, 2010-2014
Figure III-1.3.1 Procurement value of G-CSF of all Chinese hospitals, 2004-2008
Figure III-1.4.1 Output of rh-GH in China, 2006-2009
Figure III-1.4.1 Market value of rh-GH in China, 2004-2009
Figure III-1.4.3 Forecast on rh-GH output, 2010-2014
Figure III-1.4.4 Forecast on rh-GH market value, 2010-2014
Figure III-1.6.1 Global market value of anti-tumor monoclonal antibody, 2000-2009
Figure III-1.6.2 Proportion of bio-pharmaceuticals market value in drug market, 2001-2007
Figure III-1.6.3 Proportion of anti-tumor monoclonal antibody market value in bio-pharmaceuticals market, 2007
Figure III-1.6.4 Rituximab market value in China, 2003-2008
Figure III-1.6.5 Trastuzumab market value in China, 2003-2008
Figure III-2.1 Geographical distribution of blood product manufacturers in China, 2009
Figure III-2.2 Output of human albumin in China, 2004-2009
Figure III-2.3 Average yield of human albumin in China, 2004-2008
Figure III-2.4 Number Changes in active human albumin producers, 2004-2009
Figure III-2.5 Human albumin market value in China, 2005-2009
Figure III-2.6 Lot release volume of imported human albumin, 2007-2009
Figure III-2.7 Forecast on human albumin output, 2010-2014
Figure III-2.8 Forecast on human albumin market value, 2010-2014
Figure III-3.1 Import and export situation of Chinese human vaccines, 2006-2009
Figure III-3.2 Vaccines import volume shares of import origins, 2009
Figure III-3.3 Market value of China’s vaccine industry, 2006-2009
Figure III-3.4 Lot release volume of H1N1 Influenza A vaccine in China, 2009
Figure III-3.5 Forecast on China’s H1N1 Influenza A vaccine output, 2010-2014
Figure III-3.6 Situation of domestic Inactivated Split Influenza vaccine lot release, 2007-2009
Figure III-3.7 Market capacity of Inactivated Split Influenza vaccine in China, 2007-2009
Figure III-3.8 Proportion of homemade and imported seasonal influenza vaccine in China, 2009
Figure III-3.9 Market share of seasonal influenza vaccine producers by volume in China, 2009
Figure III-3.10 Lot release volume of imported seasonal influenza vaccine in China, 2007-2009
Figure III-3.11 Forecast on China’s influenza vaccine market capacity, 2010-2014
Figure III-3.12 Proportion of lot release volume of different HBV products, 2009
Figure III-3.13 China’s HBV market capacity, 2007-2009
Figure III-3.14 Lot release volume of imported HBV in China, 2007-2009
Figure III-3.15 Forecast on HBV market capacity in China, 2010-2014
Figure III-4.2.1 Output value of RB industry and diagnostic reagents industry in China, 2005- 2009
Figure III-4.2.2 Share of different diagnostic reagents in China by output value, 2008
Figure III-4.4.1 Forecast on output value of diagnostic reagent in China, 2010-2015
Figure III-5.1.1.1 Output of four products in antibiotic industry in China, 2005-2009
Figure III-5.1.2.1 Major procedures of three steps fermentation technology for penicillin production
Figure III-5.1.3.1 Waste treatment procedure in Chinese antibiotic industry
Figure IV-1.1 Major procedure of diabetes treatment with stem cell
Figure IV-2.1 Major procedure of monoclonal antibody production
Figure IV-4.1 Major procedure of avian influenza vaccine production
Figure VIII-1.1.1 Chinese population and growth rate, 2000-2009
Figure VIII-1.1.2 Elderly population and its proportion, 2000-2009
Figure VIII-1.1.3 Per capital income and growth rate in urban areas
Figure VIII-1.1.4 Per capital income and growth rate in rural areas
Figure VIII-2.2.1 Exchange rate of CNY against USD
Figure VIII-2.2.2 Industrialization process of bio-pharmaceutical products

Part of Report: click here for sample pages

Executive Summary

After about thirty years’ development, China has scored great achievement in red biotechnology (RB). More and more pharmaceuticals are produced by biotechnology. The increasing use of red biotechnology in pharmaceutical production have generated both economic and environmental benefits.

Bio-pharmaceuticals are capturing relatively small market share, with its output value accounting for around XX% of China’s medicine industry in 2008. However, bio-pharmaceuticals have great development potential and the growth rate of its output value was higher than that of chemical medicines and Chinese medicines, with CAGR of XX% in 2004-2009. In 2009, China’s industrial output value of RB products was around USDXX million, up XX% over previous year.

- Major bio-pharmaceutical products in China

 Gene recombinant drugs

In China, the first recombinant DNA protein drug,α-interferon, was produced by Shenzhen Kexin Biotech Co., Ltd. Up to XX genetically engineered drugs had been developed in China, and the total market value reached USDXX billion.

EPO, interferon, CSF, growth hormone and insulin are the main gene recombinant drugs in China. With requirements for high-level production technology, there are only a few growth hormone manufacturers in China. But there are more than XX manufacturers in China for other products like EPO, interferon and CSF and the competition has been relatively intense.

 Blood products

After more than ten years’ development, currently China's blood products have been closed to or reached the international level.

Blood products include more than 20 kinds of products, such as human albumin, immunoglobulin, coagulation factor, etc. In China, comprehensive utilization rate of plasma has been low and main blood products in China are human albumin at present.

 Human vaccines

Currently, China is the largest vaccine producer in the world, with the most vaccine manufacturing enterprises. Lost of the enterprises are private ones.

At present, there are around XX human vaccine manufacturers in China. They can produce about XX species of vaccines to prevent XX species of infectious diseases. In recent years, China’s human vaccines output has been more than XX million doses.

 Diagnostic reagent

Diagnostic reagent can be mainly divided into three categories, biochemical diagnostic reagent, immunodiagnostic reagent and molecular diagnostic reagent.

Chinese diagnostic reagents industry has been so thriving. Its output value increased from USDXX million in 2005 to USDXX million in 2009, with CAGR XX% during this period.

- Production technology

At present, stem cell treatment, monoclonal antibody, diagnostic reagent and vaccine are the four most important research areas of red biotechnology in China.

In recent years, many Chinese bio-pharmaceutical companies have swarmed to use the foreign technologies once their patens expired, to chase the immediate profits. These companies always copy each other’s technologies. Without self-innovation, Chinese bio-pharmaceutical industry still lags behind foreign countries.

Some Chinese bio-pharmaceutical companies have realized these problems and started searching ways for development of domestic bio-pharmaceutical industry. The most popular way is bio-pharmaceutical manufacturer cooperating with biotechnology companies to reduce risk and investment. The manufacturers outsource the R&D of new products, so they can focus more on their products’ sales and promotion.

- China’s red biotechnology industry distribution

Owing to the late start-up, bio-pharmaceutical enterprises, most of which are small-scale, are scattered throughout the country. There are relatively more bio-pharmaceutical enterprises distributed in Yangtze River Delta region, the Pearl River Delta Region, North China, Central and Western regions. Total output value of top 4 production provinces, including Shandong, Jilin, Jiangsu and Henan, reached USDXX million in 2008, accounting for XX% of the national total.

......

(The rest content of this report is omitted.)

Character of CCM' Report:

This multi-client report provides a comprehensive study on the researched subject in China, from aspects of production, technology, import & export, consumption & end uses, etc.

>>
 All the producers in China, either active or idled or potential, have been sourced and contacted. Their situation has been verified and compiled as in the appendix.
>>
 The competitiveness of Chinese production has been discussed in order to uncover the mystery of ever-increasing capability of Chinese manufacturing.
>>
 The import & export analysis for the situation in the recent three years has been conducted.
>>
 The consumption pattern of the researched subject has been carried out in order to breakdown the end uses into different segments. The major end users under each major end use segments have been identified.
>>
 The scientific methodology has been employed to conduct the quantitative forecast on this subject in the future 5-10 years.

The aim of this report is to provide powerful assistance to the strategy group and the management team in making correct decision as how to penetrate the ever-increasing China market and how to catch the maximum commercial opportunities. The report is formulated independently by CCM’s professional market researchers, based on the first-hand and primary data which are analyzed by scientific methodology, confirmed with both manufacturers/end users/traders and legal authorities, and presented in a logic way.

Remark:

If you are not satisfied with the above main content, or if you would like to add additional requirements to the mentioned subject, or if you could not find your interested item(s) via the search engine, you are advised to go to Single-Client Services and Advisor, or Contact Us.